Neuroscience Research Australia, University of New South Wales, New South Wales, Australia; School of Population Health, University of New South Wales, New South Wales, Australia.
Prince of Wales Clinical School, University of New South Wales, Kensington, Australia; Dept. of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.
Gait Posture. 2021 Sep;89:178-185. doi: 10.1016/j.gaitpost.2021.07.010. Epub 2021 Jul 21.
Chemotherapy-induced peripheral neuropathy (CIPN) is reported to affect up to 70 % of cancer survivors. Despite evidence that CIPN-related impairments often translate into balance and mobility deficits, the effects on stepping and quality of gait, well-documented risk factors for falls, are unclear.
(i) Establish choice-stepping reaction time (CSRT) performance in survivors with CIPN compared to young and older healthy controls and people with Parkinson's disease; (ii) document walking stability; (iii) investigate relationships between stepping and gait data to objective and patient-reported outcomes.
41 cancer survivors with CIPN (mean (SD) age: 60.8 (9.7) years) who were ≥3months post chemotherapy, performed tests of simple and inhibitory CSRT. Walking stability measures were derived from 3-D accelerometry data during the 6-minute walk test. CIPN was assessed using neurological grading and patient-reported outcome measures (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire in CIPN Questionnaire scale EORTC CIPN20).
In both stepping tests, CIPN participants performed at the level of adults aged 10 years older and people with mild to moderate Parkinson's disease. Mean (SD) total stepping response times in both CSRT (1160 (190) milliseconds) and inhibitory CSRT (1191 (164) milliseconds) tests were not associated with objective neurological grading but were correlated with increased difficulty feeling the ground. Participants with lower-limb vibration sensation deficit had slower and more variable CSRT times. There were no associations between walking stability and objective measures of CIPN, and limited correlations with the EORTC-CIPN20.
Cancer survivors with CIPN showed deficits in voluntary stepping responses and seemed to compensate for their sensory and motor deficits by walking slower to maintain stability. Objective and patient-reported outcomes of CIPN were correlated with slower and more variable stepping response times. Future studies should aim to identify the causes of the apparent premature decline in cognitive-motor function and develop remediating interventions.
据报道,化疗引起的周围神经病(CIPN)会影响多达 70%的癌症幸存者。尽管有证据表明 CIPN 相关的损伤通常会转化为平衡和移动能力的缺陷,但对于与跌倒密切相关的步幅和步态质量的影响尚不清楚。
(i)与年轻和老年健康对照者以及帕金森病患者相比,确定患有 CIPN 的癌症幸存者的选择-踏反应时(CSRT)表现;(ii)记录行走稳定性;(iii)研究步幅和步态数据与客观和患者报告的结果之间的关系。
41 名患有 CIPN 的癌症幸存者(平均(SD)年龄:60.8(9.7)岁),在化疗后≥3 个月进行了简单和抑制性 CSRT 测试。在 6 分钟步行测试期间,从 3D 加速度计数据中得出行走稳定性测量值。使用神经学分级和患者报告的结局测量量表(欧洲癌症研究与治疗组织 CIPN 问卷量表 EORTC CIPN20)评估 CIPN。
在两项踏步测试中,CIPN 参与者的表现与年龄大 10 岁的成年人和轻度至中度帕金森病患者相当。在 CSRT(1160(190)毫秒)和抑制性 CSRT(1191(164)毫秒)测试中,平均(SD)总踏步反应时间与客观神经学分级无关,但与更难感觉到地面的感觉有关。下肢振动感觉缺陷的参与者的 CSRT 时间更慢且更不稳定。步行稳定性与 CIPN 的客观测量值之间没有关联,与 EORTC-CIPN20 的相关性也很有限。
患有 CIPN 的癌症幸存者表现出自愿踏步反应的缺陷,似乎通过更慢的行走来维持稳定性来补偿其感觉和运动缺陷。CIPN 的客观和患者报告的结果与更慢且更不稳定的踏步反应时间相关。未来的研究应旨在确定认知-运动功能明显衰退的原因,并开发补救干预措施。